PURPOSE: Radiation-induced angiosarcoma (RAS) of the chest wall/breast has a poor prognosis due to the high percentage of local failures. The efficacy and side effects of re-irradiation plus hyperthermia (reRT + HT) treatment alone or in combination with surgery were assessed in RAS patients. PATIENTS AND METHODS: RAS was diagnosed in 23 breast cancer patients and 1 patient with melanoma. These patients had previously undergone breast conserving therapy (BCT, n = 18), mastectomy with irradiation (n=5) or axillary lymph node dissection with irradiation (n = 1). Treatment consisted of surgery followed by reRT + HT (n = 8), reRT + HT followed by surgery (n = 3) or reRT + HT alone (n = 13). Patients received a mean radiation dose of 35 Gy (32-54 Gy) and 3-6 hyperthermia treatments (mean 4). Hyperthermia was given once or twice a week following radiotherapy (RT). RESULTS: The median latency interval between previous radiation and diagnosis of RAS was 106 months (range 45-212 months). Following reRT + HT, the complete response (CR) rate was 56 %. In the subgroup of patients receiving surgery, the 3-month, 1- and 3-year actuarial local control (LC) rates were 91, 46 and 46 %, respectively. In the subgroup of patients without surgery, the rates were 54, 32 and 22 %, respectively. Late grade 4 RT toxicity was seen in 2 patients. CONCLUSION: The present study shows that reRT + HT treatment--either alone or combined with surgery--improves LC rates in patients with RAS.
PURPOSE: Radiation-induced angiosarcoma (RAS) of the chest wall/breast has a poor prognosis due to the high percentage of local failures. The efficacy and side effects of re-irradiation plus hyperthermia (reRT + HT) treatment alone or in combination with surgery were assessed in RAS patients. PATIENTS AND METHODS: RAS was diagnosed in 23 breast cancerpatients and 1 patient with melanoma. These patients had previously undergone breast conserving therapy (BCT, n = 18), mastectomy with irradiation (n=5) or axillary lymph node dissection with irradiation (n = 1). Treatment consisted of surgery followed by reRT + HT (n = 8), reRT + HT followed by surgery (n = 3) or reRT + HT alone (n = 13). Patients received a mean radiation dose of 35 Gy (32-54 Gy) and 3-6 hyperthermia treatments (mean 4). Hyperthermia was given once or twice a week following radiotherapy (RT). RESULTS: The median latency interval between previous radiation and diagnosis of RAS was 106 months (range 45-212 months). Following reRT + HT, the complete response (CR) rate was 56 %. In the subgroup of patients receiving surgery, the 3-month, 1- and 3-year actuarial local control (LC) rates were 91, 46 and 46 %, respectively. In the subgroup of patients without surgery, the rates were 54, 32 and 22 %, respectively. Late grade 4 RT toxicity was seen in 2 patients. CONCLUSION: The present study shows that reRT + HT treatment--either alone or combined with surgery--improves LC rates in patients with RAS.
Authors: Marianne A A de Jong; Sabine Oldenborg; S Bing Oei; Vanessa Griesdoorn; M Willemijn Kolff; Caro C E Koning; Geertjan van Tienhoven Journal: Cancer Date: 2011-06-28 Impact factor: 6.860
Authors: Marianne Linthorst; Tomas Drizdal; Hans Joosten; Gerard C van Rhoon; Jacoba van der Zee Journal: Strahlenther Onkol Date: 2011-11-25 Impact factor: 3.621
Authors: John A Abraham; Francis J Hornicek; Adam M Kaufman; David C Harmon; Dempsey S Springfield; Kevin A Raskin; Henry J Mankin; David G Kirsch; Andrew E Rosenberg; G Petur Nielsen; Vikram Desphpande; Herman D Suit; Thomas F DeLaney; Sam S Yoon Journal: Ann Surg Oncol Date: 2007-03-14 Impact factor: 5.344
Authors: János Fodor; Zsolt Orosz; Eva Szabó; Zoltán Sulyok; Csaba Polgár; Zoltán Zaka; Tibor Major Journal: J Am Acad Dermatol Date: 2006-03 Impact factor: 11.527
Authors: Steven D Billings; Jesse K McKenney; Andrew L Folpe; Michael C Hardacre; Sharon W Weiss Journal: Am J Surg Pathol Date: 2004-06 Impact factor: 6.394
Authors: Anouk J M Rombouts; Jonathan Huising; Niek Hugen; Sabine Siesling; Philip Martin Poortmans; Iris D Nagtegaal; Johannes H W de Wilt Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Wolfgang Harms; Andreas Geretschläger; Corinne Cescato; Martin Buess; Dieter Köberle; Branca Asadpour Journal: Breast Care (Basel) Date: 2015-08-21 Impact factor: 2.860
Authors: Wolfgang Harms; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; D Krug; M D Piroth; M-L Sautter-Bihl; F Sedlmayer; R Souchon; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2016-03-01 Impact factor: 3.621